MariMed (OTCMKTS:MRMD – Get Free Report) was upgraded by equities researchers at Noble Financial to a “strong-buy” rating in a research note issued on Thursday,Zacks.com reports.
MariMed Stock Performance
OTCMKTS MRMD opened at $0.09 on Thursday. MariMed has a fifty-two week low of $0.07 and a fifty-two week high of $0.34. The firm has a market capitalization of $33.04 million, a P/E ratio of -2.17 and a beta of 2.75. The stock’s fifty day moving average is $0.11 and its two-hundred day moving average is $0.13. The company has a debt-to-equity ratio of 1.01, a quick ratio of 0.73 and a current ratio of 1.55.
MariMed (OTCMKTS:MRMD – Get Free Report) last issued its earnings results on Wednesday, March 5th. The company reported ($0.01) EPS for the quarter, hitting analysts’ consensus estimates of ($0.01). MariMed had a negative net margin of 10.97% and a negative return on equity of 2.75%. The company had revenue of $39.00 million for the quarter, compared to the consensus estimate of $42.00 million.
MariMed Company Profile
MariMed Inc engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature’s Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby’s Baked brand; and drink mix under Vibations brand.
Featured Stories
- Five stocks we like better than MariMed
- ETF Screener: Uses and Step-by-Step Guide
- Archer Aviation’s Africa Deal Could Boost ACHR Stock
- 3 Healthcare Dividend Stocks to Buy
- Are Short Sellers Wrong About These 3 Semiconductor Stocks?
- Stock Market Upgrades: What Are They?
- Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?
Receive News & Ratings for MariMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MariMed and related companies with MarketBeat.com's FREE daily email newsletter.
